US First-Half 1996 Health Sector Lobbying Spend

29 September 1996

At least $400 million was spent in first-half 1996 in trying to influence the US federal government, reports an Associated Press analysis of the first disclosures under a new lobbying act.

While the figure is the most comprehensive yet of the amount special interests spend, experts feel it is conservative as it ignores money spent on grass-roots lobbying and because the first half of 1996 was a quieter than usual period for lobbyists.

Some of the largest spenders were health care-related, including: American Medical Association, $8.5 million; Chemical Manufacturers Association, $4.5 million; Pfizer, $4.2 million; Health Insurance Association of America, $3.3 million; Blue Cross/Blue Shield, $2.5 million; Glaxo Wellcome, $2.1 million; Merck & Co, $1.9 million; American Hospital Association, $1.8 million; American Insurance Association, $1.7 million; Aetna, $1.3 million; and Prudential, $1.3 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight